VERI 101
Alternative Names: VERI-101Latest Information Update: 20 Jun 2024
At a glance
- Originator VerImmune
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action CD8 positive T lymphocyte stimulants; Cytotoxic T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 08 Apr 2024 Pharmacodynamics data from a preclinical study in Cacner presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 20 Sep 2023 VerImmune announces intention to submit an IND application for VERI 101 in Cancer
- 02 Nov 2022 VerImmune receives SBIR grant from National Science Foundation for VERI 101 development in Cancer